Alitair Pharmaceuticals Receives Orphan Drug Designation for Erdosteine® In Bronchiectasis
1/7/2014 9:06:42 AM
MORRISTOWN, N.J.--(BUSINESS WIRE)--Alitair Pharmaceuticals, Inc., today announced that the Office of Orphan Products Development (OOPD) of the Food and Drug Administration (FDA) has granted orphan drug designation for its drug candidate, Erdosteine®, for the treatment of bronchiectasis. Erdosteine is a mucolytic with antibacterial, anti-inflammatory, and antioxidant properties.
Help employers find you! Check out all the jobs and post your resume.
comments powered by